Skip to content
Screener

Immunome IMNM Business Segments — Interest Income Expense Net

Similar metrics at other companies

Dogwood Therapeutics logo
DWTXSingle Reportable — Interest Income Expense Net
$77.35K+153%
Vertex, Inc. logo
VERXSingle Reportable — Interest Income Expense Net
-$957K+37.8%
NEC
NECBSingle Reportable — Interest Income Expense Net
$24.65M-1.7%
Citizens & Northern logo
CZNCSingle Reportable — Interest Income Expense Net
$29.62M+40.1%
Apple Hospitality logo
APLEReportable — Interest Income Expense Net
-$20.82M+0.7%
Mcgrath Rentcorp logo
MGRCPortable Storage — Interest Income Expense Net
$808K+129%

Other financials

Income statement

See full
Revenue--100%
Operating income-$59.3M-32.9%
Net income-$53.8M-29.3%
EPS (diluted)-$0.48+7.7%

Balance sheet

See full
Cash & equivalents$582.7M+126%
Total debt$3.7M-22.6%
Total equity$588.7M+91.7%
Total assets$619.8M+80.9%

Cash flow

See full
Operating cash flow-$58.6M-10.5%
CapEx$3.0M-18.1%
Free cash flow-$61.6M-8.7%

Valuation

See full
Market cap$2.92B+221%
Enterprise value$2.35B+204%
P/S728.3×+656×

Profitability

See full
Operating margin-5,947.9%-12,002pp
Net margin-5,593.8%-11,284pp
FCF margin-5,118.9%-8,601pp

Returns & leverage

See full
Return on equity-50.1%-10.8pp
Debt / equity0.0×
Current ratio21.7×+11.2×

Where this comes from

Reported directly by Immunome in its filing.

Tagged under the XBRL concept us-gaap:InterestIncomeExpenseNet.

The source filing: Immunome’s 10-Q, filed May 12, 2026.

Filed
May 12, 2026, 4:10 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-219425
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Other direct research and development9,9714,673
Indirect research and development(2)16,31410,337
General and administrative(3)8,6497,376
Other segment expenses(4)8,5566,314
Total operating expenses59,33147,562
Loss from operations(59,331)(44,636)
Interest income5,4922,996
Net loss$(53,839)$(41,640)

Item 1. Financial Statements.

FAQ

What is Immunome's business segments — interest income expense net?
Immunome (IMNM) reported business segments — interest income expense net of $5.49M in Q1 2026.
How has Immunome's business segments — interest income expense net changed year-over-year?
Immunome's business segments — interest income expense net increased by 83.3% year-over-year, from $3M to $5.49M.
What is the long-term trend for Immunome's business segments — interest income expense net?
Over 2 years (2023 to 2025), Immunome's business segments — interest income expense net has grown at a 107.4% compound annual growth rate (CAGR), from $2.72M to $11.72M.
What does business segments — interest income expense net mean?
The net result of interest income earned on cash and investments minus interest expenses incurred on debt or other financial obligations. This metric reflects the company's treasury management and the cost of its capital structure. A positive value indicates the company is generating returns on its cash reserves, while a negative value indicates a cost of borrowing.

Ask your AI about Immunome's business segments — interest income expense net.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude